Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Trikafta (copackaged)

Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor

RLDNDA 212273 2 strengths Vertex Pharms Inc
Approved
Oct 21, 2019
Strengths
2
Listed patents
30
Applications
2

What does the FDA Orange Book show for Trikafta (copackaged)?

Trikafta (copackaged) contains Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor and appears in 2 FDA Orange Book applications. NDA 212273 is the lead filing, with 2 presentations shown in detail; the other exact-name filings are listed separately. The page preserves strength, dosage form, route, status, RLD/RS, TE, patent, and exclusivity facts. Clinical labeling requires an exact application-matched source.

FDA applications
2; lead NDA 212273

Every filing shown uses the exact FDA product name; the lead filing supplies the detailed presentation view.

Lead application holder
Vertex Pharmaceuticals Inc

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
2

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Prescription

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD / RS

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
None posted

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
30

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
8

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
001100MG,75MG,50MG; 150MGTABLETORALPrescriptionNone posted
RLDRS
00250MG,37.5MG,25MG; 75MGTABLETORALPrescriptionNone posted
RLD

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Vertex Pharmaceuticals Inc

The Orange Book identifies this organization as the applicant responsible for NDA 212273.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

2 presentations listed as prescription

RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.

Therapeutic equivalence

No TE code is posted for this application

No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.

Patent & exclusivity record

29 listed patent expirations and 8 exclusivity dates remain on or after Jul 26, 2026

The latest future date recorded across those files is Jul 17, 2038. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

0 other ANDAs and 0 other NDAs found

0 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 212273 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Tablet · Oral

Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor

1 application
Product rows
2
Active applications
1
Active with AB row
0

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-212273

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Strengths & dosage forms

2 approved presentations · NDA 212273
RLDRS
Strength
100MG,75MG,50MG; 150MG
Dosage form
TABLET
Route
ORAL
Marketing status
Prescription

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    6 yr 10 mo ago

  2. Patent 8354427 expires

    Listed method-of-use patent (U-3029) expiration.

    20 d ago

  3. Patent 8354427 expires

    Listed method-of-use patent (U-3145) expiration.

    20 d ago

  4. Today

  5. Exclusivity ends · ODE-275

    Orphan-drug exclusivity (7 years)

    in 3 mo

  6. Patent 8410274 expires

    Listed drug product patent expiration.

    in 5 mo

  7. Patent 8754224 expires

    Listed drug substance patent expiration.

    in 5 mo

  8. Patent 9670163 expires

    Listed drug product patent expiration.

    in 5 mo

  9. Patent 9670163 expires

    Listed drug product patent expiration.

    in 5 mo

  10. Patent 9670163 expires

    Listed drug product patent expiration.

    in 5 mo

  11. Patent 9670163 expires

    Listed drug product patent expiration.

    in 5 mo

  12. Patent 9931334 expires

    Listed drug product patent expiration.

    in 5 mo

  13. Patent 9931334 expires

    Listed drug product patent expiration.

    in 5 mo

  14. Patent 9931334 expires

    Listed drug product patent expiration.

    in 5 mo

  15. Patent 9931334 expires

    Listed drug product patent expiration.

    in 5 mo

  16. Patent 10022352 expires

    Listed drug product patent expiration.

    in 9 mo

  17. Patent 10022352 expires

    Listed drug product patent expiration.

    in 9 mo

  18. Patent 10239867 expires

    Listed drug substance patent expiration.

    in 9 mo

  19. Patent 10239867 expires

    Listed drug substance patent expiration.

    in 9 mo

  20. Patent 10239867 expires

    Listed drug substance patent expiration.

    in 9 mo

  21. Patent 10239867 expires

    Listed drug substance patent expiration.

    in 9 mo

  22. Patent 11639347 expires

    Listed drug substance patent expiration.

    in 9 mo

  23. Patent 11639347 expires

    Listed drug substance patent expiration.

    in 9 mo

  24. Patent 11639347 expires

    Listed drug substance patent expiration.

    in 9 mo

  25. Patent 9974781 expires

    Listed drug product patent expiration.

    in 9 mo

  26. Patent 9974781 expires

    Listed drug product patent expiration.

    in 9 mo

  27. Patent 9974781 expires

    Listed drug product patent expiration.

    in 9 mo

  28. Patent 9974781 expires

    Listed drug product patent expiration.

    in 9 mo

  29. Patent 7645789 expires

    Listed drug substance patent expiration.

    in 9 mo

  30. Patent 8598181 expires

    Listed method-of-use patent (U-3028) expiration.

    in 9 mo

  31. Patent 8598181 expires

    Listed method-of-use patent (U-3144) expiration.

    in 9 mo

  32. Patent 8598181 expires

    Listed method-of-use patent (U-4056) expiration.

    in 9 mo

  33. Patent 8598181 expires

    Listed method-of-use patent (U-4475) expiration.

    in 9 mo

  34. Patent 8623905 expires

    Listed drug substance patent expiration.

    in 9 mo

  35. Patent 7495103 expires

    Listed drug substance patent expiration.

    in 10 mo

  36. Patent 7776905 expires

    Listed drug substance patent expiration.

    in 10 mo

  37. Patent 8324242 expires

    Listed method-of-use patent (U-4073) expiration.

    in 1 yr 1 mo

  38. Patent 8324242 expires

    Listed method-of-use patent (U-3028) expiration.

    in 1 yr 1 mo

  39. Patent 8324242 expires

    Listed method-of-use patent (U-3144) expiration.

    in 1 yr 1 mo

  40. Patent 8324242 expires

    Listed method-of-use patent (U-4475) expiration.

    in 1 yr 1 mo

  41. Patent 8415387 expires

    Listed method-of-use patent (U-4073) expiration.

    in 1 yr 4 mo

  42. Patent 8415387 expires

    Listed method-of-use patent (U-3028) expiration.

    in 1 yr 4 mo

  43. Patent 8415387 expires

    Listed method-of-use patent (U-3144) expiration.

    in 1 yr 4 mo

  44. Patent 8415387 expires

    Listed method-of-use patent (U-4475) expiration.

    in 1 yr 4 mo

  45. Exclusivity ends · M-313

    New use / labeling-change exclusivity (3 years)

    in 1 yr 5 mo

  46. Exclusivity ends · ODE-323

    Orphan-drug exclusivity (7 years)

    in 1 yr 5 mo

  47. Exclusivity ends · ODE-357

    Orphan-drug exclusivity (7 years)

    in 1 yr 11 mo

  48. Patent 10646481 expires

    Listed drug product patent expiration.

    in 3 yr 1 mo

  49. Patent 11564916 expires

    Listed method-of-use patent (U-3525) expiration.

    in 3 yr 1 mo

  50. Patent 11564916 expires

    Listed method-of-use patent (U-4063) expiration.

    in 3 yr 1 mo

  51. Patent 11564916 expires

    Listed method-of-use patent (U-4491) expiration.

    in 3 yr 1 mo

  52. Patent 12458635 expires

    Listed drug product patent expiration.

    in 3 yr 1 mo

  53. Patent 12458635 expires

    Listed drug product patent expiration.

    in 3 yr 1 mo

  54. Patent 10081621 expires

    Listed drug product patent expiration.

    in 4 yr 9 mo

  55. Patent 10081621 expires

    Listed drug product patent expiration.

    in 4 yr 9 mo

  56. Patent 10081621 expires

    Listed drug product patent expiration.

    in 4 yr 9 mo

  57. Patent 10081621 expires

    Listed drug product patent expiration.

    in 4 yr 9 mo

  58. Patent 11578062 expires

    Listed drug product patent expiration.

    in 4 yr 9 mo

  59. Patent 11578062 expires

    Listed drug product patent expiration.

    in 4 yr 9 mo

  60. Patent 11578062 expires

    Listed drug product patent expiration.

    in 4 yr 9 mo

  61. Patent RE50453 expires

    Listed drug substance patent expiration.

    in 5 yr

  62. Exclusivity ends · ODE-512

    Orphan-drug exclusivity (7 years)

    in 5 yr 6 mo

  63. Exclusivity ends · ODE-543

    Orphan-drug exclusivity (7 years)

    in 6 yr 9 mo

  64. Patent 9012496 expires

    Listed method-of-use patent (U-2649) expiration.

    in 7 yr 1 mo

  65. Patent 9012496 expires

    Listed method-of-use patent (U-3154) expiration.

    in 7 yr 1 mo

  66. Patent 10758534 expires

    Listed drug substance patent expiration.

    in 9 yr 4 mo

  67. Patent 10758534 expires

    Listed drug substance patent expiration.

    in 9 yr 4 mo

  68. Patent 10758534 expires

    Listed drug substance patent expiration.

    in 9 yr 4 mo

  69. Patent 10758534 expires

    Listed drug substance patent expiration.

    in 9 yr 4 mo

  70. Patent 11426407 expires

    Listed drug substance patent expiration.

    in 9 yr 4 mo

  71. Patent 11426407 expires

    Listed drug substance patent expiration.

    in 9 yr 4 mo

  72. Patent 11426407 expires

    Listed drug substance patent expiration.

    in 9 yr 4 mo

  73. Patent 10793547 expires

    Listed drug substance patent expiration.

    in 11 yr 6 mo

  74. Patent 10793547 expires

    Listed drug substance patent expiration.

    in 11 yr 6 mo

  75. Patent 10793547 expires

    Listed drug substance patent expiration.

    in 11 yr 6 mo

  76. Patent 10793547 expires

    Listed drug substance patent expiration.

    in 11 yr 6 mo

  77. Patent 11179367 expires

    Listed drug product patent expiration.

    in 11 yr 6 mo

  78. Patent 11179367 expires

    Listed drug product patent expiration.

    in 11 yr 6 mo

  79. Patent 11179367 expires

    Listed drug product patent expiration.

    in 11 yr 6 mo

  80. Patent 11453655 expires

    Listed drug substance patent expiration.

    in 11 yr 6 mo

  81. Patent 11517564 expires

    Listed drug product patent expiration.

    in 11 yr 6 mo

  82. Patent 11517564 expires

    Listed drug product patent expiration.

    in 11 yr 6 mo

  83. Patent 11517564 expires

    Listed drug product patent expiration.

    in 11 yr 6 mo

  84. Patent 12350262 expires

    Listed method-of-use patent (U-4221) expiration.

    in 12 yr 2 mo

  85. Patent 12350262 expires

    Listed method-of-use patent (U-4475) expiration.

    in 12 yr 2 mo

Patent & exclusivity timeline

Protection horizon
2026202820302032203420362038TodayPatent 8354427: 2026-07-06Patent 8354427Patent 8354427: 2026-07-06Patent 8354427Exclusivity ODE-275: 2026-10-21Exclusivity ODE-275Patent 8410274: 2026-12-28Patent 8410274Patent 8754224: 2026-12-28Patent 8754224Patent 9670163: 2026-12-28Patent 9670163Patent 9670163: 2026-12-28Patent 9670163Patent 9670163: 2026-12-28Patent 9670163Patent 9670163: 2026-12-28Patent 9670163Patent 9931334: 2026-12-28Patent 9931334Patent 9931334: 2026-12-28Patent 9931334Patent 9931334: 2026-12-28Patent 9931334Patent 9931334: 2026-12-28Patent 9931334Patent 10022352: 2027-04-09Patent 10022352Patent 10022352: 2027-04-09Patent 10022352Patent 10239867: 2027-04-09Patent 10239867Patent 10239867: 2027-04-09Patent 10239867Patent 10239867: 2027-04-09Patent 10239867Patent 10239867: 2027-04-09Patent 10239867Patent 11639347: 2027-04-09Patent 11639347Patent 11639347: 2027-04-09Patent 11639347Patent 11639347: 2027-04-09Patent 11639347Patent 9974781: 2027-04-09Patent 9974781Patent 9974781: 2027-04-09Patent 9974781Patent 9974781: 2027-04-09Patent 9974781Patent 9974781: 2027-04-09Patent 9974781Patent 7645789: 2027-05-01Patent 7645789Patent 8598181: 2027-05-01Patent 8598181Patent 8598181: 2027-05-01Patent 8598181Patent 8598181: 2027-05-01Patent 8598181Patent 8598181: 2027-05-01Patent 8598181Patent 8623905: 2027-05-01Patent 8623905Patent 7495103: 2027-05-20Patent 7495103Patent 7776905: 2027-06-03Patent 7776905Patent 8324242: 2027-08-05Patent 8324242Patent 8324242: 2027-08-05Patent 8324242Patent 8324242: 2027-08-05Patent 8324242Patent 8324242: 2027-08-05Patent 8324242Patent 8415387: 2027-11-12Patent 8415387Patent 8415387: 2027-11-12Patent 8415387Patent 8415387: 2027-11-12Patent 8415387Patent 8415387: 2027-11-12Patent 8415387Exclusivity M-313: 2027-12-20Exclusivity M-313Exclusivity ODE-323: 2027-12-21Exclusivity ODE-323Exclusivity ODE-357: 2028-06-08Exclusivity ODE-357Patent 10646481: 2029-08-13Patent 10646481Patent 11564916: 2029-08-13Patent 11564916Patent 11564916: 2029-08-13Patent 11564916Patent 11564916: 2029-08-13Patent 11564916Patent 12458635: 2029-08-13Patent 12458635Patent 12458635: 2029-08-13Patent 12458635Patent 10081621: 2031-03-25Patent 10081621Patent 10081621: 2031-03-25Patent 10081621Patent 10081621: 2031-03-25Patent 10081621Patent 10081621: 2031-03-25Patent 10081621Patent 11578062: 2031-03-25Patent 11578062Patent 11578062: 2031-03-25Patent 11578062Patent 11578062: 2031-03-25Patent 11578062Patent RE50453: 2031-07-10Patent RE50453Exclusivity ODE-512: 2031-12-20Exclusivity ODE-512Exclusivity ODE-543: 2033-03-27Exclusivity ODE-543Patent 9012496: 2033-07-15Patent 9012496Patent 9012496: 2033-07-15Patent 9012496Patent 10758534: 2035-10-06Patent 10758534Patent 10758534: 2035-10-06Patent 10758534Patent 10758534: 2035-10-06Patent 10758534Patent 10758534: 2035-10-06Patent 10758534Patent 11426407: 2035-10-06Patent 11426407Patent 11426407: 2035-10-06Patent 11426407Patent 11426407: 2035-10-06Patent 11426407Patent 10793547: 2037-12-08Patent 10793547Patent 10793547: 2037-12-08Patent 10793547Patent 10793547: 2037-12-08Patent 10793547Patent 10793547: 2037-12-08Patent 10793547Patent 11179367: 2037-12-08Patent 11179367Patent 11179367: 2037-12-08Patent 11179367Patent 11179367: 2037-12-08Patent 11179367Patent 11453655: 2037-12-08Patent 11453655Patent 11517564: 2037-12-08Patent 11517564Patent 11517564: 2037-12-08Patent 11517564Patent 11517564: 2037-12-08Patent 11517564Patent 12350262: 2038-07-17Patent 12350262Patent 12350262: 2038-07-17Patent 12350262
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

Strength

100MG,75MG,50MG; 150MG

Dosage form

TABLET

Route

ORAL

TE code

Not listed

Application

NDA 212273

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Marketing exclusivity

Hatch-Waxman
  • ODE-275Orphan-drug exclusivity (7 years)

    in 3 mo

  • M-313New use / labeling-change exclusivity (3 years)

    in 1 yr 5 mo

  • ODE-323Orphan-drug exclusivity (7 years)

    in 1 yr 5 mo

  • ODE-357Orphan-drug exclusivity (7 years)

    in 1 yr 11 mo

  • ODE-512Orphan-drug exclusivity (7 years)

    in 5 yr 6 mo

  • ODE-543Orphan-drug exclusivity (7 years)

    in 6 yr 9 mo

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
835442720 d ago
U-3029
835442720 d ago
U-3145
8410274in 5 mo
Product
8754224in 5 mo
SubstanceProduct
9670163in 5 mo
ProductU-4078
9670163in 5 mo
ProductU-3031
9670163in 5 mo
ProductU-3155
9670163in 5 mo
ProductU-4477
9931334in 5 mo
ProductU-4078
9931334in 5 mo
ProductU-3031
9931334in 5 mo
ProductU-3155
9931334in 5 mo
ProductU-4479
10022352in 9 mo
ProductU-2651
10022352in 9 mo
ProductU-3156
10239867in 9 mo
SubstanceProductU-3158
10239867in 9 mo
SubstanceProductU-4056
10239867in 9 mo
SubstanceProductU-3033
10239867in 9 mo
SubstanceProductU-4475
11639347in 9 mo
SubstanceProductU-3587
11639347in 9 mo
SubstanceProductU-4056
11639347in 9 mo
SubstanceProductU-4475
9974781in 9 mo
ProductU-3028
9974781in 9 mo
ProductU-3144
9974781in 9 mo
ProductU-4073
9974781in 9 mo
ProductU-4475
7645789in 9 mo
SubstanceProduct
8598181in 9 mo
U-3028
8598181in 9 mo
U-3144
8598181in 9 mo
U-4056
8598181in 9 mo
U-4475
8623905in 9 mo
SubstanceProduct
7495103in 10 mo
SubstanceProduct
7776905in 10 mo
SubstanceProduct
8324242in 1 yr 1 mo
U-4073
8324242in 1 yr 1 mo
U-3028
8324242in 1 yr 1 mo
U-3144
8324242in 1 yr 1 mo
U-4475
8415387in 1 yr 4 mo
U-4073
8415387in 1 yr 4 mo
U-3028
8415387in 1 yr 4 mo
U-3144
8415387in 1 yr 4 mo
U-4475
10646481in 3 yr 1 mo
Product
11564916in 3 yr 1 mo
U-3525
11564916in 3 yr 1 mo
U-4063
11564916in 3 yr 1 mo
U-4491
12458635in 3 yr 1 mo
ProductU-4330
12458635in 3 yr 1 mo
ProductU-4486
10081621in 4 yr 9 mo
ProductU-4075
10081621in 4 yr 9 mo
ProductU-3032
10081621in 4 yr 9 mo
ProductU-3157
10081621in 4 yr 9 mo
ProductU-4480
11578062in 4 yr 9 mo
ProductU-3544
11578062in 4 yr 9 mo
ProductU-4054
11578062in 4 yr 9 mo
ProductU-4490
RE50453in 5 yr
SubstanceProduct
9012496in 7 yr 1 mo
U-2649
9012496in 7 yr 1 mo
U-3154
10758534in 9 yr 4 mo
SubstanceProductU-3144
10758534in 9 yr 4 mo
SubstanceProductU-4073
10758534in 9 yr 4 mo
SubstanceProductU-3028
10758534in 9 yr 4 mo
SubstanceProductU-4475
11426407in 9 yr 4 mo
SubstanceProductU-3425
11426407in 9 yr 4 mo
SubstanceProductU-4070
11426407in 9 yr 4 mo
SubstanceProductU-4475
10793547in 11 yr 6 mo
SubstanceProductU-3144
10793547in 11 yr 6 mo
SubstanceProductU-3028
10793547in 11 yr 6 mo
SubstanceProductU-4073
10793547in 11 yr 6 mo
SubstanceProductU-4475
11179367in 11 yr 6 mo
ProductU-3253
11179367in 11 yr 6 mo
ProductU-4071
11179367in 11 yr 6 mo
ProductU-4487
11453655in 11 yr 6 mo
SubstanceProduct
11517564in 11 yr 6 mo
ProductU-3498
11517564in 11 yr 6 mo
ProductU-4067
11517564in 11 yr 6 mo
ProductU-4475
12350262in 12 yr 2 mo
U-4221
12350262in 12 yr 2 mo
U-4475

Other FDA applications for Trikafta (copackaged)

1 additional filing

The FDA has approved 2 separate applications under this product name. Each row is one application: a distinct applicant and approval for the same drug.

Other FDA applications approved under the product name Trikafta (copackaged), with applicant, approval date, number of strengths, therapeutic-equivalence code, and marketing status.
ApplicationApplicantApprovedStrengthsTE codeStatus
NDA 217660Vertex Pharms IncApr 26, 20232—Prescription

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

No other applications share this active ingredient.

View full Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Trikafta (copackaged): frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 212273 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo